Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings Inc (INFU) delivers essential medical equipment and outpatient care services across North America, specializing in infusion therapy solutions for oncology, pain management, and chronic care. This page provides investors and healthcare professionals with timely updates on the company's operational milestones and strategic initiatives.
Access consolidated INFU news including earnings announcements, regulatory filings, and partnership developments. Our repository features press releases related to medical device innovations, service expansions, and leadership updates – all critical for assessing the company's position in the durable medical equipment sector.
Key content categories include quarterly financial results, biomedical service enhancements, and coverage of INFU's dual-platform strategy balancing patient care with device lifecycle management. Bookmark this page to monitor INFU's progress in bridging clinical and home-based healthcare delivery.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a national distribution agreement with Genadyne Biotechnologies, enhancing its portfolio in negative pressure wound therapy (NPWT). InfuSystem will distribute Genadyne’s complete line of wound care products, including the advanced XLR8 Plus NPWT Pump and XLR8 Dressing Kit with Silver. This partnership aims to address supply chain challenges and provide diverse wound care solutions, ultimately improving patient outcomes and reducing healthcare costs. InfuSystem emphasizes its commitment to facilitating outpatient care and enhancing service delivery in the durable medical equipment sector.
InfuSystem Holdings, Inc. (NYSE American: INFU) reported record net revenues of $109.9 million for 2022, marking a 7% increase from 2021. The fourth quarter net revenues reached $28.8 million, a 9% year-over-year increase. Key segments include Integrated Therapy Services (ITS) with $68.9 million and Durable Medical Equipment (DME) at $41.0 million, growing 5% and 12% respectively. Adjusted EBITDA for 2022 was $20.7 million, down 14%. The company projects 2023 revenue growth of 8% to 10% with an Adjusted EBITDA margin over 19%. Management remains optimistic about strategic partnerships and growth in pain management services.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
